Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351103 · ClinicalTrials.gov registry record · Phase 1
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase 1 study of Pancreatic Cancer and Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT01351103 is a Phase 1 study of Pancreatic Cancer and Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 185 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01351103, a Phase 1 study of Pancreatic Cancer and Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite standard therapy or for which no effective standard therapy existed.
Conditions Studied
Interventions
- DRUG LGK974
- BIOLOGICAL PDR001
Study Locations (20)
Other
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Essen
- Novartis Investigative Site - Naples
- Novartis Investigative Site - Utrecht
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
Catalonia
- Novartis Investigative Site - Barcelona
- Novartis Investigative Site - Barcelona
- Novartis Investigative Site - L'Hospitalet de Llobregat
Michigan
- University of Michigan Comprehensive Cancer Center Onc Dept. - Ann Arbor
- Karmanos Cancer Institute Wayne St - Detroit
California
- UCLA School of Medicine - Los Angeles
Maryland
- Sidney Kimmel Comprehensive Cancer Center Johns Hopkins - Baltimore
Massachusetts
- Dana Farber Cancer Institute SC-7 - Boston
Texas
- University of Texas/MD Anderson Cancer Center MD Anderson 2 - Houston
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2011-12-01 |
| Est. Completion | 2024-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01351103
The ClinicalTrials.gov registry entry for NCT01351103 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (53% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which LGK974 is the first listed.
NCT01351103 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Catalonia, Michigan.
Frequently Asked Questions
What is clinical trial NCT01351103 about?
NCT01351103 is a clinical study titled "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands". The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite standard therapy or for which no effective standard therapy existed.
What is the current status of trial NCT01351103?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 185 participants. The study started on 2011-12-01. Estimated completion is 2024-06-17.
What conditions does trial NCT01351103 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Melanoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Cancer, Esophageal Squamous Cell Cancer.
What interventions are being tested in trial NCT01351103?
The interventions under investigation include: LGK974 (DRUG), PDR001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01351103?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01351103 being conducted?
This trial has 20 study locations across California, Maryland, Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.